Enovix Corp. (ENVX)
3.315
-0.06
(-1.63%)
USD |
NASDAQ |
Sep 04, 16:00
3.33
+0.02
(+0.45%)
After-Hours: 16:15
Enovix R&D to Revenue (TTM)
R&D to Revenue (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical R&D to Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -- |
| March 31, 2026 | -- |
| December 31, 2025 | -- |
| September 30, 2025 | -- |
| June 30, 2025 | -- |
| March 31, 2025 | -- |
| December 31, 2024 | -- |
| September 30, 2024 | -- |
| June 30, 2024 | -- |
| Date | Value |
|---|---|
| March 31, 2024 | -- |
| December 31, 2023 | -- |
| September 30, 2023 | -- |
| June 30, 2023 | -- |
| March 31, 2023 | -- |
| December 31, 2022 | -- |
| September 30, 2022 | -- |
| June 30, 2022 | -- |
R&D to Revenue Definition
The Research & Development (R&D) Expense to Revenue ratio measures the percentage of sales that is allocated to R&D expenditures. It is not as effective when looking at companies in different industries because different industries place different values on R&D. Technology companies and pharmaceutical companies are more likely to have high R&D ratios.
R&D to Revenue (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median